DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Sriparna Roy - 2 Krishna Chandra - 2 BioXcel - 2 Karen Kharmandarian - 1 Kharmandarian - 1 bullish - 1 Splunk - 1 Stocks - 1
Top related locs:
Bengaluru Macau Chile Cayman Pasadena , California U.S Salt Lake City , Utah Wells Fargo
Top related orgs:
BioXcel Therapeutics - 6 Thomson - 3 CNBC - 2 Cisco Systems - 2 Nasdaq - 2 BioXcel Therapeutics Inc - 2 Big Tech - 1 Apple - 1

Search resuls for: "BioXcel"


8 mentions found


☆ Forget Big Tech? Fund manager names 6 lesser-known tech stocks to buy instead
  + stars: | 2023-11-22 | by ( Amala Balakrishner | ) www.cnbc.com   time to read: +5 min
One portfolio manager, however, is shifting his focus to other tech players — particularly small mid-cap names. His comments come despite the sharp gains registered by big tech stocks which pushed the price-to-earnings ratio of the S & P 500 index to around 20 times. By contrast, the ratio is trading below 14 times when the seven Big Tech stocks are excluded, he noted. Another stock in Kharmandarian's AI and Robotics Fund fund is cybersecurity firm Crowdstrike . Electronic Design Automation Another theme on Kharmandarian's watchlist is electronic design automation — specifically companies designing the latest generations of semiconductors.
Persons: Karen Kharmandarian, Kharmandarian, bullish, Splunk Organizations: Big Tech, Apple, Microsoft, Nvidia, Tesla, Thematics Asset Management, CNBC, Robotics Fund, Cisco Systems, Cadence Design Systems, Pharmaceuticals, BioXcel Therapeutics
☆ What we'd like to see from 3 economic readings and 2 earnings reports next week
  + stars: | 2023-11-11 | by ( Zev Fima | ) www.cnbc.com   time to read: +9 min
The major averages advanced again this week as earnings results came in largely better than expected, interest rates stabilized and oil prices dropped below $80 a barrel. Looking ahead, we'll get a couple more earnings results and some key inflationary data to chew on. In this past week, we bought 150 shares of DuPont (DD) and added 75 shares of Wynn Resorts (WYNN). As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.
Persons: Stocks, Wynn Resort's, WYNN, we'll, That's, —, we're, it's, PANW, Tyson, Henry Schein, Spero, Sanara, Sara Lee Corp, JD.com, Woodward, Jim Cramer's, Jim Cramer, Jim, Mario Anzuoni Organizations: Nasdaq, Dow Jones, Coterra Energy, Emerson, Disney, PPI, TJX, Palo Alto Networks, DuPont, Wynn Resorts, WYNN, Tyson Foods, TSN, Tower Semiconductor, Partners, Genius Sports, Spero Therapeutics, Star Bulk Carriers Corp, Beauty Health, Asure, Gladstone Capital Corp, TeraWulf Inc, Harrow Health, Afya, Sea, Paysafe Group Holdings, Solar Inc, Aramark Holdings Corp, Lending, Holding, BioXcel Therapeutics, IHS Inc, Rewalk Robotics, Acurx Pharmaceuticals, Energizer Holdings, Power Solutions, Rekor Systems, Wine Estates, Momentus Inc, SIGMA Lithium Corporation, AlTi, QuickLogic Corporation, Arcturus Therapeutics, Dada Nexus, Solutions, Target Corp, Parts, ZIM Integrated Shipping Services, Alto Networks, Cisco Systems, Chemical & Mining Co, PennantPark Investment Corp, Copa Holdings S.A, Walmart, Arcos Dorados Holdings, ARCO, NICE, Body, Warner Music Group Corp, Ross Stores, Homes, Dolby Laboratories Inc, American Software, ESCO Technologies, ZTO, International, BJ's Wholesale, Jim Cramer's Charitable, CNBC, Maxx Locations: Macau, Chile, Cayman, Pasadena , California
☆ BioXcel to cut over 50% of jobs as it pivots focus to agitation drug
  + stars: | 2023-08-14 | by ( ) www.reuters.com   time to read: +2 min
Companies BioXcel Therapeutics Inc FollowAug 14 (Reuters) - BioXcel Therapeutics Inc (BTAI.O) said on Monday it will reduce its workforce by more than 50% to 80 employees from about 190, as the drugmaker shifts its focus towards developing its agitation treatment. The drug, sold under the brand name Igalmi in the U.S., is already approved for use in hospital settings to treat agitation in adult patients with schizophrenia or bipolar disorder. The company plans to reduce in-hospital commercialization expenses, and suspend trials that it no longer deems core to its business. With the job cuts, BioXcel aims to reduce more than 50% of its cash burn to about $80 million on a go-forward annualized basis. Its cash and cash equivalents totaled to $127.5 million as of June 30, compared with $165.5 million as of March 31.
Persons: Sriparna Roy, Krishna Chandra Organizations: BioXcel Therapeutics, BioXcel Therapeutics Inc, Oaktree Fund Administration, Qatar Investment Authority, Thomson Locations: U.S, Bengaluru
☆ BioXcel announces job cuts to focus on agitation related treatment
  + stars: | 2023-08-14 | by ( ) www.reuters.com   time to read: 1 min
Companies BioXcel Therapeutics Inc FollowAug 14 (Reuters) - BioXcel Therapeutics Inc (BTAI.O) said on Monday it will reduce its workforce to 80 employees from about 190, as the drugmaker shifts its focus to treatments for agitation. The company said it will prioritize development of its drug BXCL501, being evaluated for use in at-home settings for treatment of agitation related to schizophrenia, bipolar disorders and in patients with mild-to-moderate dementia due to probable Alzheimer's disease. Shares of the company were halted during premarket trading. Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra EluriOur Standards: The Thomson Reuters Trust Principles.
Persons: Sriparna Roy, Krishna Chandra Organizations: BioXcel Therapeutics, BioXcel Therapeutics Inc, Thomson Locations: Bengaluru
☆ These are the most heavily shorted stocks right now
  + stars: | 2023-07-28 | by ( Samantha Subin Nick Wells | Samantha Subin | Nick Wells | ) www.cnbc.com   time to read: +2 min
Investors upped their short bets on a handful of clean energy and biotechnology stocks during the first half of July, according to FactSet data. Allogene Therapeutics held the greatest short interest of the group, at about 54% of float, with Novavax and ProKidney Corp. also appearing on the list. Short interest declined slightly in ProKidney shares. Short interest in shares declined 8.6% during the first half of July, although about 35% of its shares are sold short. saw short interest leap 10% since the end of June.
Persons: BioXcel Organizations: BioXcel Therapeutics, Allogene Therapeutics, ProKidney Corp, Research, CNBC Pro, New York Stock Exchange, Nasdaq
☆ BioXcel cites issues at Alzheimer's drug trial site, shares plunge
  + stars: | 2023-06-29 | by ( Khushi Mandowara | ) www.reuters.com   time to read: +2 min
June 29 (Reuters) - BioXcel Therapeutics (BTAI.O) flagged issues related to the recording of safety data at one of the sites for late-stage trial of its Alzheimer's drug, sending its shares plunging more than 67% in premarket trading on Thursday. The drug, named BXCL501, was being studied to treat patients with agitation related to Alzheimer's disease. The issue highlighted by the company overshadowed results of the drug's trial, which was also reported on Thursday. BioXcel said it plans to submit an application to expand the use of the drug in the second half of this year. The drug is already approved by the FDA for treating agitation associated with schizophrenia or bipolar I or II disorder in adults.
Persons: Vimal Mehta, Robyn Karnauskas, BioXcel, Khushi Mandowara, Krishna Chandra Eluri Organizations: BioXcel Therapeutics, U.S . Food, Drug Administration, Truist Securities, Thomson Locations: Bengaluru
☆ Stocks making the biggest moves midday: Occidental Petroleum, Wells Fargo, Micron, Joby and more
  + stars: | 2023-06-29 | by ( Brian Evans | ) www.cnbc.com   time to read: +2 min
Analyst Adam Jonas's $13 price target implies more than 70% upside from Wednesday's close for the stock. Wells Fargo climbed 3.4% while JPMorgan and Bank of America added more than 2% each. Tenaris — The pipe manufacturer rose 2.4% after Jefferies initiated coverage of the stock at a buy, citing a compelling risk-reward ratio. Occidental Petroleum - Shares of the oil giant rose nearly 1% after Warren Buffett's Berkshire Hathaway once again increased its stake. Sigilon Therapeutics — Shares soared more than 500% on news that pharmaceutical company Eli Lilly would purchase Sigilon for as much as $126.56 per share.
Persons: Freyr — Freyr Battery, Morgan Stanley, Adam Jonas's, Wells, Jefferies, Warren Buffett's Berkshire Hathaway, Eli Lilly, — CNBC's Michelle Fox, Alex Harring, Sarah Min, Yun Li Organizations: JPMorgan Chase, Bank of America —, JPMorgan, Bank of America, Micron Technology, Micron, Occidental Petroleum, Occidental, Joby, SK Telecom, Sigilon Therapeutics, Therapeutics, Food and Drug Administration Locations: Salt Lake City , Utah, Wells Fargo, China, Occidental, Houston
☆ Cramer's lightning round: BioXcel Therapeutics may be home run or nothing
  + stars: | 2022-11-17 | by ( Krystal Hur | ) www.cnbc.com   time to read: 1 min
Loading chart...4D Molecular Therapeutics Inc : "Regeneron is the horse to bet on, because it's been a great investment." Loading chart...SoFi Technologies Inc : "I do believe it's bottoming, but I don't know what gets it higher." Loading chart...BioXcel Therapeutics Inc : "It may be home run or nothing, and that's always tough." Loading chart...Veru Inc : "The test for [the company's Covid treatment pill] ... The FDA staff didn't seem to like it."
0 next >>
Total: 8